Surrozen, a biotech company focused on eye disease therapies, announced it will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026. The presentation will highlight Surrozen's innovative Wnt signaling-based treatments for sight-threatening conditions. Investors can access the live webcast and replay on Surrozen's website. This event provides Surrozen an opportunity to showcase its progress and future plans, including its development pipeline and partnership with Boehringer Ingelheim.
Morgan Stanley increased its price target for United Airlines to $190, suggesting nearly 60% upside from the current price of $118.81. The airline's stock has surged 235% since October 2023, driven by a strong rebound in international travel and rais...
Citizens Financial Group reported a strong Q2 performance with earnings per share of $1.30, surpassing estimates by 4% and marking a 41% increase year-over-year. The bank also posted revenue of $2.28 billion, beating expectations and continuing a fou...
Yara International ASA is set to release its Q2 2026 earnings on July 17, with analysts expecting an EPS of $1.19 and revenue of $5.14 billion. The fertilizer industry faces challenges from rising raw material costs and potential demand decline due t...
Cycurion received a Nasdaq delisting notice due to its stock price falling below the $1 minimum for 31 consecutive days. The company is appealing the decision, which allows its shares to keep trading on Nasdaq during the review. Cycurion is focused o...
TDb Split Corp. plans a 15-for-100 share split for its Class A shares, effective for shareholders of record on July 24, 2026, pending TSX approval. Following the split, shareholders will receive the same $0.05 monthly cash distribution per share, eff...
